FDA approves Bristol-Myers' drug for rare fat disorder

Feb 25 (Reuters) - Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved its drug to treat rare and potentially fatal disorders involving loss of body fat.

The condition, known as generalized lipodystrophy, involves fat buildup in the blood and organs such as liver and muscle and can lead to diabetes, pancreatitis and fatty liver disease.

The company said the FDA had asked the drugmaker to conduct seven post-marketing studies on the drug, Myalept. ()